MX2017010552A - Receptor antigenico quimerico. - Google Patents
Receptor antigenico quimerico.Info
- Publication number
- MX2017010552A MX2017010552A MX2017010552A MX2017010552A MX2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A MX 2017010552 A MX2017010552 A MX 2017010552A
- Authority
- MX
- Mexico
- Prior art keywords
- chimeric antigen
- antigen receptor
- car
- coiled
- association
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 125000006850 spacer group Chemical group 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
- A61K39/464411—Immunoglobulin superfamily
- A61K39/464412—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464454—Enzymes
- A61K39/464462—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
- A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the structure of the chimeric antigen receptor [CAR]
- A61K2239/23—On/off switch
- A61K2239/24—Dimerizable CARs; CARs with adapter
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Abstract
La presente invención proporciona un polipéptido formador de receptor antigénico quimérico (CAR) que comprende: (i) un dominio de unión a antígenos; (ii) un dominio espaciador de hélice superenrollada; (iii) un dominio transmembranal; y (iv) un endodominio. La invención también proporciona un CAR multimérico formado por la asociación de una pluralidad de polipéptidos formadores de CAR en virtud de la asociación de sus dominios espaciadores de hélice superenrollada.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1504840.8A GB201504840D0 (en) | 2015-03-23 | 2015-03-23 | Chimeric antigen receptor |
PCT/GB2016/050795 WO2016151315A1 (en) | 2015-03-23 | 2016-03-22 | Chimeric antigen receptor |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2017010552A true MX2017010552A (es) | 2018-03-14 |
MX371384B MX371384B (es) | 2020-01-28 |
Family
ID=53052211
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2017010552A MX371384B (es) | 2015-03-23 | 2016-03-22 | Receptor antigenico quimerico. |
Country Status (21)
Country | Link |
---|---|
US (1) | US11058722B2 (es) |
EP (1) | EP3274366B8 (es) |
JP (3) | JP6675417B2 (es) |
KR (1) | KR102174280B1 (es) |
CN (1) | CN107406518B (es) |
AU (1) | AU2016238583B2 (es) |
BR (1) | BR112017018252A2 (es) |
CA (1) | CA2978852C (es) |
CL (1) | CL2017002413A1 (es) |
DK (1) | DK3274366T3 (es) |
ES (1) | ES2773527T3 (es) |
GB (1) | GB201504840D0 (es) |
HU (1) | HUE047929T2 (es) |
IL (1) | IL254254B (es) |
MX (1) | MX371384B (es) |
PL (1) | PL3274366T3 (es) |
PT (1) | PT3274366T (es) |
RU (1) | RU2752880C2 (es) |
SG (1) | SG11201706940QA (es) |
WO (1) | WO2016151315A1 (es) |
ZA (1) | ZA201705682B (es) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2948544A4 (en) | 2013-01-28 | 2016-08-03 | St Jude Childrens Res Hospital | CHIMERIC RECEPTOR WITH NKG2D SPECIFICITY FOR CELL THERAPY AGAINST CANCER AND INFECTION DISEASES |
US20230027993A1 (en) | 2014-03-05 | 2023-01-26 | Autolus Limited | Methods |
US11385233B2 (en) | 2015-03-05 | 2022-07-12 | Autolus Limited | Methods of depleting malignant T-cells |
GB201403972D0 (en) | 2014-03-06 | 2014-04-23 | Ucl Business Plc | Chimeric antigen receptor |
GB201405845D0 (en) | 2014-04-01 | 2014-05-14 | Ucl Business Plc | Signalling system |
US10428305B2 (en) | 2014-05-15 | 2019-10-01 | National University Of Singapore | Modified natural killer cells that express IL15 and uses thereof |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
GB201501936D0 (en) * | 2015-02-05 | 2015-03-25 | Ucl Business Plc | Signalling system |
PL3298033T5 (pl) | 2015-05-18 | 2023-10-30 | TCR2 Therapeutics Inc. | Kompozycje i zastosowania medyczne do reprogramowania TCR z zastosowaniem białek fuzyjnych |
EP3443001A4 (en) | 2016-04-11 | 2020-04-29 | Obsidian Therapeutics, Inc. | REGULATED BIOCIRCUIT SYSTEMS |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
JP7109789B2 (ja) | 2016-08-02 | 2022-08-01 | ティーシーアール2 セラピューティクス インク. | 融合タンパク質を使用したtcrの再プログラム化のための組成物及び方法 |
IL292551B2 (en) | 2016-10-07 | 2023-10-01 | Tcr2 Therapeutics Inc | Preparations and methods for reprogramming T-cell receptors using fusion proteins |
US11851491B2 (en) | 2016-11-22 | 2023-12-26 | TCR2 Therapeutics Inc. | Compositions and methods for TCR reprogramming using fusion proteins |
CA3056591A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Stimulatory cell lines for ex vivo expansion and activation of natural killer cells |
CA3056439A1 (en) | 2017-03-27 | 2018-10-04 | National University Of Singapore | Truncated nkg2d chimeric receptors and uses thereof in natural killer cell immunotherapy |
WO2018176144A1 (en) * | 2017-03-29 | 2018-10-04 | Sunnybrook Research Institute | Engineered t-cell modulating molecules and methods of using same |
US11166985B2 (en) | 2017-05-12 | 2021-11-09 | Crispr Therapeutics Ag | Materials and methods for engineering cells and uses thereof in immuno-oncology |
EP3621981A2 (en) | 2017-05-12 | 2020-03-18 | CRISPR Therapeutics AG | Materials and methods for engineering cells and uses thereof in immuno-oncology |
JP2020530993A (ja) * | 2017-08-02 | 2020-11-05 | オートラス リミテッド | キメラ抗原受容体または改変tcrを発現し、選択的に発現されるヌクレオチド配列を含む細胞 |
EP3704150A1 (en) | 2017-11-01 | 2020-09-09 | F. Hoffmann-La Roche AG | The compbody - a multivalent target binder |
GB201801831D0 (en) * | 2018-02-05 | 2018-03-21 | Autolus Ltd | Chimeric receptor |
EP3790629A1 (en) | 2018-05-11 | 2021-03-17 | CRISPR Therapeutics AG | Methods and compositions for treating cancer |
JP7335272B2 (ja) | 2018-05-15 | 2023-08-29 | オートラス リミテッド | キメラ抗原受容体 |
GB201807870D0 (en) | 2018-05-15 | 2018-06-27 | Autolus Ltd | A CD79-specific chimeric antigen receptor |
WO2020037178A1 (en) * | 2018-08-16 | 2020-02-20 | Memorial Sloan-Kettering Cancer Center | Leucine zipper-based compositions and methods of use |
CN109265550B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Bcma抗体、嵌合抗原受体和药物 |
MX2021003636A (es) | 2018-09-27 | 2021-07-21 | Autolus Ltd | Receptor antigenico quimerico. |
CA3112310A1 (en) * | 2018-10-05 | 2020-04-09 | St. Anna Kinderkrebsforschung | A group of chimeric antigen receptors (cars) |
US20220041718A1 (en) | 2018-10-31 | 2022-02-10 | Autolus Limited | Binding domain |
WO2020180882A1 (en) | 2019-03-05 | 2020-09-10 | Nkarta, Inc. | Cd19-directed chimeric antigen receptors and uses thereof in immunotherapy |
MA55372A (fr) | 2019-03-21 | 2022-01-26 | Regeneron Pharma | Combinaison d'inhibiteurs de la voie il-4/il-13 et d'ablation de plasmocytes pour traiter une allergie |
US20220249558A1 (en) | 2019-04-30 | 2022-08-11 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
GB201919017D0 (en) | 2019-12-20 | 2020-02-05 | Autolus Ltd | Cell |
CN111234033B (zh) * | 2020-01-21 | 2021-05-11 | 南京北恒生物科技有限公司 | 多链嵌合抗原受体及其用途 |
GB202004263D0 (en) | 2020-03-24 | 2020-05-06 | Autolus Ltd | Antibody conjugate |
GB202005216D0 (en) | 2020-04-08 | 2020-05-20 | Autolus Ltd | Cell |
GB202006820D0 (en) | 2020-05-07 | 2020-06-24 | Autolus Ltd | Cell |
GB202017649D0 (en) | 2020-11-09 | 2020-12-23 | Autolus Ltd | Polypeptide |
WO2022204326A1 (en) * | 2021-03-24 | 2022-09-29 | The Regents Of The University Of California | Humanized synthetic notch receptors with augmented transactivation domains and uses thereof |
GB202115329D0 (en) * | 2021-10-25 | 2021-12-08 | Autolus Ltd | Chimeric cytokine receptor |
WO2024019961A1 (en) * | 2022-07-18 | 2024-01-25 | Cargo Therapeutics, Inc. | Cd2 recruiting chimeric antigen receptors and fusion proteins |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081443B2 (en) | 2002-05-21 | 2006-07-25 | Korea Advanced Institutes Of Science And Technology (Kaist) | Chimeric comp-ang1 molecule |
WO2010102518A1 (zh) | 2009-03-13 | 2010-09-16 | 北京表源生物技术有限公司 | 一种融合蛋白多聚体 |
KR101156085B1 (ko) * | 2010-01-29 | 2012-06-20 | 국립암센터 | 4-1bb리간드(4-1bbl)오중합체 및 이의 용도 |
US10745467B2 (en) * | 2010-03-26 | 2020-08-18 | The Trustees Of Dartmouth College | VISTA-Ig for treatment of autoimmune, allergic and inflammatory disorders |
JP6053688B2 (ja) * | 2011-10-07 | 2016-12-27 | 国立大学法人三重大学 | キメラ抗原受容体 |
MA37681B2 (fr) * | 2012-05-25 | 2020-07-29 | Cellectis | Procédés pour modifier des lymphocytes t résistants allogéniques et immunosuppresseurs pour l'immunothérapie |
CN104769103B (zh) * | 2012-09-04 | 2018-06-08 | 塞勒克提斯公司 | 多链嵌合抗原受体和其用途 |
SI3613439T1 (sl) * | 2013-02-15 | 2021-11-30 | The Regents Of The University Of California | Himerni antigenski receptor in postopki njegove uporabe |
CN103145849B (zh) * | 2013-02-18 | 2014-06-11 | 冯振卿 | 嵌合抗原受体及其用途 |
EP3083671B1 (en) * | 2013-12-20 | 2020-09-30 | Fred Hutchinson Cancer Research Center | Tagged chimeric effector molecules and receptors thereof |
ES2767423T3 (es) | 2014-01-13 | 2020-06-17 | Hope City | Receptores de antígenos quiméricos (CARS) con mutaciones en la región del espaciador Fc y métodos para su uso |
GB201415347D0 (en) | 2014-08-29 | 2014-10-15 | Ucl Business Plc | Signalling system |
GB201610512D0 (en) | 2016-06-16 | 2016-08-03 | Autolus Ltd | Chimeric antigen receptor |
-
2015
- 2015-03-23 GB GBGB1504840.8A patent/GB201504840D0/en not_active Ceased
-
2016
- 2016-03-22 JP JP2017549766A patent/JP6675417B2/ja active Active
- 2016-03-22 RU RU2017132978A patent/RU2752880C2/ru active
- 2016-03-22 MX MX2017010552A patent/MX371384B/es active IP Right Grant
- 2016-03-22 BR BR112017018252-1A patent/BR112017018252A2/pt active Search and Examination
- 2016-03-22 EP EP16712424.7A patent/EP3274366B8/en active Active
- 2016-03-22 SG SG11201706940QA patent/SG11201706940QA/en unknown
- 2016-03-22 US US15/560,558 patent/US11058722B2/en active Active
- 2016-03-22 PL PL16712424T patent/PL3274366T3/pl unknown
- 2016-03-22 DK DK16712424.7T patent/DK3274366T3/da active
- 2016-03-22 CN CN201680017370.3A patent/CN107406518B/zh active Active
- 2016-03-22 PT PT167124247T patent/PT3274366T/pt unknown
- 2016-03-22 WO PCT/GB2016/050795 patent/WO2016151315A1/en active Application Filing
- 2016-03-22 HU HUE16712424A patent/HUE047929T2/hu unknown
- 2016-03-22 ES ES16712424T patent/ES2773527T3/es active Active
- 2016-03-22 CA CA2978852A patent/CA2978852C/en active Active
- 2016-03-22 AU AU2016238583A patent/AU2016238583B2/en active Active
- 2016-03-22 KR KR1020177030391A patent/KR102174280B1/ko active IP Right Grant
-
2017
- 2017-08-21 ZA ZA2017/05682A patent/ZA201705682B/en unknown
- 2017-08-31 IL IL254254A patent/IL254254B/en active IP Right Grant
- 2017-09-25 CL CL2017002413A patent/CL2017002413A1/es unknown
-
2020
- 2020-01-09 JP JP2020001971A patent/JP2020048588A/ja not_active Withdrawn
-
2022
- 2022-12-16 JP JP2022201192A patent/JP2023021396A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2017010552A (es) | Receptor antigenico quimerico. | |
MX2021012720A (es) | Celulas t de receptor de antigeno quimerico co-estimulador que toman como diana a il13r-alfa-2. | |
CA2929984C (en) | A t cell or natural killer (nk) cell which co-expresses two chimeric antigen receptors (cars) | |
MX2022000132A (es) | Inmunoreceptores especificos de claudina-18.2 y epitopos de celulas t. | |
AU2018260863A1 (en) | Human IgG1 Fc region variants and uses thereof | |
ZA201804829B (en) | Psma and cd3 bispecific t cell engaging antibody constructs | |
BR112016022369A2 (pt) | receptores quiméricos de antígeno cd33-específicos para imunoterapia contra o câncer | |
MX2017009182A (es) | Sistemas de receptor de antigeno quimerico impulsado por mab para clasificar/reducir celulas inmunes diseñadas. | |
MX2018013738A (es) | Anticuerpos que comprenden dominios constantes quimericos. | |
MX2017003640A (es) | Receptores antigenicos quimericos. | |
EA201792042A1 (ru) | T-клетка, которая экспрессирует t-клеточный рецептор (tcr) гамма-дельта и химерный антигенный рецептор (car) | |
MX2016012713A (es) | Inmunoreceptores especificos de claudina-6 y epitopos de celulas t. | |
MX2022002364A (es) | Anticuerpos anti-pd-l1. | |
NZ728674A (en) | Signalling system | |
BR112016019643A2 (pt) | receptores químéricos de antígeno específico de cd123 para imunoterapia anticancerígena | |
HK1223943A1 (zh) | 嵌合的靶向抗原受體的單克隆抗體 | |
PH12015502572A1 (en) | Chimeric fvii-xten molecules and uses thereof | |
UA113879C2 (xx) | ГУМАНІЗОВАНЕ АНТИТІЛО ПРОТИ ТrkА З АМІНОКИСЛОТНИМИ ЗАМІЩЕННЯМИ | |
BR112018006991A2 (pt) | receptores de antígeno quiméricos direcionados ao psca | |
WO2017066481A8 (en) | Chimeric antigen receptors containing a chlorotoxin domain | |
WO2014190305A3 (en) | Anti-gpiib/iiia antibodies or uses thereof | |
WO2013115410A3 (en) | Anti-phospholipase d4 antibody | |
PH12015501650A1 (en) | Human antibody specific to human metapneumovirus, or antigen-binding fragment thereof | |
EP3478320A4 (en) | MONOCLONAL ANTIBODIES AGAINST SIGNALING OF THE KILLERIMMUNOGLOBULIN LIKE RECIPE (KIR) FAMILY | |
NZ758571A (en) | Chimeric antigen receptors based on single-domain antibodies and methods of use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
HC | Change of company name or juridical status |
Owner name: AUTOLUS LTD Owner name: RESPIVERT LTD. |
|
FG | Grant or registration | ||
PD | Change of proprietorship |
Owner name: AUTOLUS LIMITED |